BIPI Independent Medical Education Grant
Boehringer Ingelheim Pharmaceuticals, Inc. (BIPI) - BI Cares FoundationSuggest an update
Grant amount: Unspecified amount
Applicant type: Organizations
Funding uses: Conference, Education / Outreach
Location of project: United States
Location of residency: United StatesView website Save
About this funder:
Boehringer Ingelheim Pharmaceuticals, Inc. (BIPI) is proud to provide Independent Medical Education Grant support for specific independent educational activities for healthcare providers that may translate to better management of disease and improvement in patient safety and population health. An independent educational program may be at the national, regional or local level and may include but is not limited to, live and interactive didactic presentations (e.g., symposia at major educational meetings, grand rounds, regional workshops), web-based programs, print and electronic monographs and other innovative educational formats.
BIPI considers funding of activities both independently and through its alliance arrangement with Lilly USA, LLC (Lilly) in a variety of areas including:
BIPI Areas of Strategic Focus
- Improve HCP knowledge of identifying best practices for assessing disease severity and diagnosis of pustular psoriasis in adult patients.
- Enhance HCP understanding of recent pathophysiological findings in pustular psoriasis, GPP, and PPP that have informed the selection of new therapeutic targets.
- Educate HCPs on the clinical profiles and mechanisms of action of new and emerging agents for the treatment of adults with GPP and PPP.
Non-Small Cell Lung Cancer
- Increase clinicians’ understanding of the heterogeneity of disease among patients with NSCLC and the clinical impact of distinguishing between subpopulations (e.g. different histologies, different sub-types) to optimize therapeutic strategies.
- Increase clinicians’ understanding of treating patients with EGFR positive NSCLC in the light of resistance mechanism after 1st line treatment with anti-EGFR agents.
- Review the management of adverse events associated with the use of oral anti-EGFR agents.
- Increase clinicians’ understanding of biology, incidence and treatment options for patients with NSCLC and uncommon EGFR mutations.
- Increase clinicians’ awareness of Real World Data in patients with EGFR+ advanced NSCLC and its implications on patient management decisions.
- Increase clinicians’ understanding of appropriate testing for advanced disease, emerging data on relevant genomic biomarkers and the changing treatment landscape in patients with metastatic squamous NSCLC.
Chronic Obstructive Pulmonary Disease (COPD)
- Expand clinicians’ awareness of different inhaler device types and to provide practical considerations for patient prescribing.
- Expand clinicians’ knowledge of the role of Peak Inspiratory Flow Rate.
- Expand clinicians’ awareness to identify the role of different drug classes in COPD management as it pertains to safety and efficacy.
- Identify the role of dual bronchodilation for the management of COPD as it relates to the 2020 GOLD recommendation.
- Expand clinicians’ awareness and knowledge of the GOLD/ATS/ERS guidelines for a more individualized management of COPD.
Interstitial Lung Disease (ILD)
- Disease course, diagnosis and risk assessment: Increase clinicians’ understanding of disease prevalence, morbidity and mortality, burden of illness, and signs and symptoms of ILD (IPF, Connective Tissue Disease (CTD) related ILD). Additionally improve clinician’s knowledge of recommended diagnostic testing methods and interpretation (e.g. HRCT, surgical biopsy, serologic testing) and the importance of routine, comprehensive multidisciplinary assessments in patients with CTD-ILD.
- Earlier identification and differentiation of ILDs: Raise the index of awareness of ILD among HCPs to encourage earlier referral of appropriate patients with ILD (IPF and Connective Tissue Disease related ILD) to ILD centers.
- Treatment guidelines and clinical management: Improve clinicians’ knowledge regarding IPF clinical management, including developments in clinical research and treatment guidelines.
- IPF risk factors and co-morbidities: Increase understanding among pulmonologists regarding management of the possible IPF risk factors (such as pharmacogenetics, pharmacogenomics) and co-morbidities for IPF (such as GERD), as well as the importance of managing other co-morbidities.
- HCP communication with patients: Improve clinicians understanding of how to effectively communicate and educate ILD patients about their disease.
Systemic Sclerosis Interstitial Lung Disease (SSc-ILD)
- Disease course, diagnosis and risk assessment: Increase clinicians’ understanding of disease pathophysiology, prevalence, morbidity and mortality and signs and symptom of SSc-ILD. Additionally improve clinician’s knowledge about the need to evaluate and monitor lung involvement in patients with SSc (e.g. HRCT scan, PFTs).
- Treatment guidelines and clinical management: Improve clinicians’ knowledge regarding SSc-ILD clinical management, including developments in clinical research and treatment guidelines.
- HCP communication with patients: Improve clinicians understanding of how to effectively communicate and educate SSc-ILD patients about their disease.
Chronic Fibrosing Interstitial Lung Diseases (ILDs) with a Progressive Phenotype
- Description of Chronic Fibrosing ILDs with a Progressive Phenotype: Improve clinician’s knowledge about the diseases most commonly associated with ILDs with a Progressive Phenotype (i.e. Rheumatoid Arthritis, Chronic Hypersensitivity Pneumonitis, Unclassified ILD) and the need to monitor lung involvement in patients with these diseases.
- Disease course, diagnosis and assessment: Increase clinicians’ understanding of disease pathophysiology, prevalence, morbidity and mortality, and signs and symptoms of ILDs with a Progressive Phenotype.
- Clinical management: Improve clinicians’ knowledge regarding clinical management of ILDs with a Progressive Phenotype, including developments in clinical research and treatment guidelines.
BIPI/Lilly Alliance Therapeutic Areas
Therapeutic Areas of interest supported by the Boehringer Ingelheim Pharmaceutical Inc (BIPI) and Eli Lilly and Company (Lilly) global Alliance agreement:
Educational Objectives - Cardiometabolism
- Increase clinicians’ ability to apply the current guidelines and leverage the latest scientific evidence in clinical practice while managing the cardiovascular risk in patients with Type 2 diabetes
- Improve clinicians’ understanding of the unmet medical needs, clinical practice guidelines, and emerging scientific evidence regarding treatment of patients with Heart Failure with or without concomitant diabetes
- Improve clinicians’ understanding of the current guidelines and scientific evidence regarding treatment of patients with Chronic Kidney Disease and Type 2 diabetes
You can learn more about this opportunity by visiting the funder's website.
- A medical education grant must be designed to support independent medical education for healthcare providers and patients that may translate to better management of disease and improvement in patient safety and population health.
- Grant applications must be submitted no less than 60 days prior to the program start date.
Find more grants like this
Find more grants like the BIPI Independent Medical Education Grant by joining Instrumentl.
We help nonprofits and academics find more grants and take control of their grants process with a refreshingly intuitive online platform.